<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Roche-CH1499059983">Roche</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/roche-ramps-up-ai-computing-capacity-with-nvidia-chip-expansion-2026-03-16/">Roche ramps up AI computing capacity with Nvidia chip expansion</a>
    </div>

      <div class="me-0 me-md-5">
        Swiss drugmaker Roche said on Monday it had expanded its artificial intelligence computing ​capacity with more than 2,100 Nvidia ‌chips to support drug and diagnostics development.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Roche-CH1499059983">Roche</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/16/3256740/0/en/Roche-launches-NVIDIA-AI-factory-to-accelerate-the-development-of-new-therapeutics-and-diagnostics-solutions.html">Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions</a>
    </div>

      <div class="me-0 me-md-5">
        Basel, 16 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that an expansion of its global AI infrastructure, deploying a large-scale AI factory powered by a full stack of the latest-generation NVIDIA accelerated computing and AI. Featuring 2,176 high-performance GPUs on premises across the United States and Europe and embedded across the entire value chain, this infrastructure i...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Roche-CH1499059983">Roche</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/roche-receives-ce-mark-for-first-ivd-immunoassay-blood-test-to-identify-carriers-of-apoe4-a-genetic-variant-present-in-up-to-60-of-patients-diagnosed-with-alzheimers-disease-302714082.html">Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer&#39;s disease</a>
    </div>

      <div class="me-0 me-md-5">
        The Elecsys ApoE4 test is the first CE marked in-vitro diagnostic immunoassay to identify individuals carrying the ApoE4 genetic variant using a simple blood sample. The test offers a fast, reliable and accessible option to rapidly differentiate between carriers and non-carriers.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Roche-CH1499059983">Roche</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">AD HOC NEWS</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.ad-hoc-news.de/boerse/news/ueberblick/roche-holding-ag-aktie-isin-ch0012032048-unter-woechentlichem-druck/68686876">Die Roche Holding AG Aktie (ISIN: CH0012032048) schloss bei 320,70 CHF und verzeichnete trotz täglichem Plus einen wöchentlichen Verlust von 8,76 Prozent. Analysten sehen Upside-Potenzial, während Diagnostik-Schwäche und Pipeline-Stärken im Fokus stehen – relevant für Schweizer, deutsche und österreichische Portfolios.</a>
    </div>

      <div class="me-0 me-md-5">
        Roche Holding AG Aktie (ISIN: CH0012032048) unter wöchentlichem Druck – Chancen für DACH-Anleger?
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Roche-CH1499059983">Roche</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">AD HOC NEWS</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.ad-hoc-news.de/boerse/news/ueberblick/roche-holding-ag-aktie-isin-ch0012032048-unter-woechentlichem-druck/68688949">Die Roche Holding AG Aktie (ISIN: CH0012032048) schloss am 13. März 2026 bei 320,70 CHF nach einem wöchentlichen Rückgang von 8,76 Prozent. Trotz Diagnostik-Schwäche bleibt der Buy-Konsens intakt, mit attraktiver Bewertung für DACH-Anleger.</a>
    </div>

      <div class="me-0 me-md-5">
        Roche Holding AG Aktie (ISIN: CH0012032048) unter wöchentlichem Druck – Analysten sehen 18-Prozent-Upside
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Roche-CH1499059983">Roche</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">AD HOC NEWS</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.ad-hoc-news.de/boerse/news/ueberblick/bepanthen-derma-rich-repairing-body-cream-der-neue-star-unter-den/68679538">Bepanthen Derma Rich Repairing Body Cream in 400 ml erobert als Bestseller die Märkte. Warum dieses Produkt für trockene Haut in der DACH-Region entscheidend ist und was Investoren der Roche-Aktie (ISIN: CH0012032048) daraus mitnehmen können.</a>
    </div>

      <div class="me-0 me-md-5">
        Bepanthen Derma Rich Repairing Body Cream: Der neue Star unter den hautpflegenden Bodylotions
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Roche-CH1499059983">Roche</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">AD HOC NEWS</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.ad-hoc-news.de/boerse/news/ueberblick/roche-holding-ag-aktie-unter-druck-klinikstudien-rueckschlag-trifft/68668968">Die Roche Holding AG Aktie (ISIN: CH0012032048) gerät nach dem Scheitern des Brustkrebs-Medikaments giredestrant in eine Abwärtsphase. Analysten sind geteilter Meinung, während der Kurs auf 323 CHF abrutscht – was bedeutet das für DACH-Anleger?</a>
    </div>

      <div class="me-0 me-md-5">
        Roche Holding AG Aktie unter Druck: Klinikstudien-Rückschlag trifft Brustkrebs-Kandidat
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Roche-CH1499059983">Roche</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Seeking Alpha</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4880980-harbor-health-care-etf-q4-2025-portfolio-review">Harbor Health Care ETF Q4 2025 Portfolio Review</a>
    </div>

      <div class="me-0 me-md-5">
        Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly delivered strong absolute performance — driven by continued GLP-1 demand and the FDA approval of Zepbound — our underweight position in the name was a significant detractor from relative results. During...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Roche-CH1499059983/load_more?page=6">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>